BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%

TORONTO, ONTARIO--(Marketwired - Sept. 15, 2016) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 28^th annual PROFIT 500, the definitive ranking of Canada's Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

Based on a five-year revenue growth rate of 815% (2010-2015), BioSyent ranked 92nd on the 2016 PROFIT 500 list. This is the fourth consecutive year that BioSyent has been named to the PROFIT 500 list and the second consecutive year that it has been ranked in the top 100 fastest-growing companies.

"We are proud to be named to the PROFIT 500 list for the fourth consecutive year," commented René Goehrum, President and CEO of BioSyent. "We remain committed to building our brand portfolio with innovative products and continuing to execute on our strategy to deliver consistent, profitable growth."

"Companies become a part of the PROFIT 500 through innovative thinking, smart strategy and sheer grit," says James Cowan, Editor-in-chief of PROFIT and Canadian Business. "These firms demonstrate what Canadian entrepreneurs can achieve, both at home and across the globe."

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,091,087 shares issued and outstanding.